DIY drug administration on rise

Market research group Greystone Research Associates estimates that the global value of non-oral drug self-administration will exceed $130 billion in 2014. Greystone lists four major factors as propelling non-oral self-delivery: an increase in approved drugs that just don't work in oral form, added cost and strain on the healthcare system that comes with patient visits to caregivers for drug treatments, availability of patient-friendly delivery methods, and a desire by patients to avoid routine caregiver visits. This presents a market opportunity for developers of user-friendly devices and delivery systems, Greystone says. Release | Report highlights

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.